MAPK-activated protein kinase-2 regulates physiological bone turnover
Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is a main target of MAPK p38, a key intracellular signal transduction molecule mediating osteoclastogenesis and inflammation. MK2 deficient mice are healthy and fertile in contrast to p38 deficient mice. Aim of this study is to...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2011-03, Vol.70 (Suppl 2), p.A21-A22 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A22 |
---|---|
container_issue | Suppl 2 |
container_start_page | A21 |
container_title | Annals of the rheumatic diseases |
container_volume | 70 |
creator | Braun, Tobias Lepper, Johannes Lezuo, Patrick Schett, Georg Zwerina, Jochen |
description | Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is a main target of MAPK p38, a key intracellular signal transduction molecule mediating osteoclastogenesis and inflammation. MK2 deficient mice are healthy and fertile in contrast to p38 deficient mice. Aim of this study is to determine whether MK2 contributes to the regulation of physiological bone turnover and to identify a potential mechanism. To determine the bone phenotype the authors analysed a Tartrate resistant acid phosphatase (TRAP)-staining and a goldner staining of the tibia by histomorphometrie and did a μCT scan of the tibia. The mechanical stability of the bone was detected using the four point bending experiment. Serum bone turnover markers (Osteocalcin and RatLaps) and serum level of Receptor activator of nuclear factor κB ligand (RANKL) and Osteoprotegrin (OPG) were detected by ELISA. To analyse osteoclastogenesis the authors determined the number of osteoclast precursor cells in the bone marrow by Fluoreszenz activated cell sorter (FACS) and generated osteoclasts from bone marrow cells ex vivo. To analyse intracellular signalling pathways, the authors stimulated these osteoclasts with tumour necrosis factor α (TNFα) and detected the phosphorylation of kinases by western blot. Gene expression of osteoclasts was detected by real-time PCR. Histomorphometrie showed increased trabecular volume and trabecular number and decreased trabecular separation in MK2 deficient mice compared to wildtype. The μCT analysis confirmed these results and showed an increased bone density in MK2 deficient mice. Thus the four point bending experiment demonstrated a higher mechanical stability of bone of these mice. The number of osteoclasts was reduced while the number of osteoblasts was not altered in MK2 deficient mice. Serum Osteocalcin and RatLaps levels were decreased while OPG was increased and RANKL was not altered. Ex vivo osteoclastogenesis was clearly reduced in MK2 deficient mice compared to wildtype mice while the number of CD11b precursors in the bone marrow was equal. The phosphorylation of p38, serine/threonine protein kinase (AKT) and extracellular signal regulated kinase (ERK) was increased in TNFα stimulated MK2 deficient osteoclasts. Gene expression of TRAP, osteoclast associated receptor (OSCAR), matrix metalloproteinase 9 and receptor activator of nuclear factor κB (RANK) was decreased in MK2 deficient osteoclasts. MK2 deficient mice have an increased bone density and |
doi_str_mv | 10.1136/ard.2010.148965.21 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904466431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>904466431</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2231-83673b5e5e8dc3669e93fd4bab8c62922e8336f657c1c8b4c1fc52f7adb7a7f23</originalsourceid><addsrcrecordid>eNqNkDtPwzAUhS0EEqXwB5giMTC5-BXbGauqBdryGKADi-U4TkmbJsVOKvrvcVQEEhPT1dH97tG5B4BLjAYYU36jXTYgqFNMJjweEHwEephxCQni6Bj0EEIUsoSLU3Dm_SpIJLHsgfHD8HkGtWmKnW5sFm1d3diiitZFpb2FJHJ22ZZh5aPt-94XdVkvC6PLKK0rGzWtq-qddefgJNeltxffsw9eJ-OX0R2cP93ej4ZzmBJCMZSUC5rGNrYyM5TzxCY0z1iqU2k4SQixklKe81gYbGTKDM5NTHKhs1RokRPaB9cH3xDzo7W-UZvCG1uWurJ161WCGOOcURzIqz_kqg5hQziFhRCSJywWgSIHyrjae2dztXXFRru9wkh1xapQrOqKVYdiFems4eGo8I39_LnQbq3CeyJWj4uRmi7e6HQymyv2y6eb1X_8vwBTQ4hj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777869457</pqid></control><display><type>article</type><title>MAPK-activated protein kinase-2 regulates physiological bone turnover</title><source>BMJ Journals - NESLi2</source><creator>Braun, Tobias ; Lepper, Johannes ; Lezuo, Patrick ; Schett, Georg ; Zwerina, Jochen</creator><creatorcontrib>Braun, Tobias ; Lepper, Johannes ; Lezuo, Patrick ; Schett, Georg ; Zwerina, Jochen</creatorcontrib><description>Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is a main target of MAPK p38, a key intracellular signal transduction molecule mediating osteoclastogenesis and inflammation. MK2 deficient mice are healthy and fertile in contrast to p38 deficient mice. Aim of this study is to determine whether MK2 contributes to the regulation of physiological bone turnover and to identify a potential mechanism. To determine the bone phenotype the authors analysed a Tartrate resistant acid phosphatase (TRAP)-staining and a goldner staining of the tibia by histomorphometrie and did a μCT scan of the tibia. The mechanical stability of the bone was detected using the four point bending experiment. Serum bone turnover markers (Osteocalcin and RatLaps) and serum level of Receptor activator of nuclear factor κB ligand (RANKL) and Osteoprotegrin (OPG) were detected by ELISA. To analyse osteoclastogenesis the authors determined the number of osteoclast precursor cells in the bone marrow by Fluoreszenz activated cell sorter (FACS) and generated osteoclasts from bone marrow cells ex vivo. To analyse intracellular signalling pathways, the authors stimulated these osteoclasts with tumour necrosis factor α (TNFα) and detected the phosphorylation of kinases by western blot. Gene expression of osteoclasts was detected by real-time PCR. Histomorphometrie showed increased trabecular volume and trabecular number and decreased trabecular separation in MK2 deficient mice compared to wildtype. The μCT analysis confirmed these results and showed an increased bone density in MK2 deficient mice. Thus the four point bending experiment demonstrated a higher mechanical stability of bone of these mice. The number of osteoclasts was reduced while the number of osteoblasts was not altered in MK2 deficient mice. Serum Osteocalcin and RatLaps levels were decreased while OPG was increased and RANKL was not altered. Ex vivo osteoclastogenesis was clearly reduced in MK2 deficient mice compared to wildtype mice while the number of CD11b precursors in the bone marrow was equal. The phosphorylation of p38, serine/threonine protein kinase (AKT) and extracellular signal regulated kinase (ERK) was increased in TNFα stimulated MK2 deficient osteoclasts. Gene expression of TRAP, osteoclast associated receptor (OSCAR), matrix metalloproteinase 9 and receptor activator of nuclear factor κB (RANK) was decreased in MK2 deficient osteoclasts. MK2 deficient mice have an increased bone density and a reduced number of osteoclasts. This is due to impaired osteoclastogenesis in consequence of reduced expression of osteoclast specific genes. Thus MK2 plays an important role in physiological bone turnover by regulating osteoclastogenesis.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2010.148965.21</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2011-03, Vol.70 (Suppl 2), p.A21-A22</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/70/Suppl_2/A21.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/70/Suppl_2/A21.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3182,23551,27903,27904,77346,77377</link.rule.ids></links><search><creatorcontrib>Braun, Tobias</creatorcontrib><creatorcontrib>Lepper, Johannes</creatorcontrib><creatorcontrib>Lezuo, Patrick</creatorcontrib><creatorcontrib>Schett, Georg</creatorcontrib><creatorcontrib>Zwerina, Jochen</creatorcontrib><title>MAPK-activated protein kinase-2 regulates physiological bone turnover</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is a main target of MAPK p38, a key intracellular signal transduction molecule mediating osteoclastogenesis and inflammation. MK2 deficient mice are healthy and fertile in contrast to p38 deficient mice. Aim of this study is to determine whether MK2 contributes to the regulation of physiological bone turnover and to identify a potential mechanism. To determine the bone phenotype the authors analysed a Tartrate resistant acid phosphatase (TRAP)-staining and a goldner staining of the tibia by histomorphometrie and did a μCT scan of the tibia. The mechanical stability of the bone was detected using the four point bending experiment. Serum bone turnover markers (Osteocalcin and RatLaps) and serum level of Receptor activator of nuclear factor κB ligand (RANKL) and Osteoprotegrin (OPG) were detected by ELISA. To analyse osteoclastogenesis the authors determined the number of osteoclast precursor cells in the bone marrow by Fluoreszenz activated cell sorter (FACS) and generated osteoclasts from bone marrow cells ex vivo. To analyse intracellular signalling pathways, the authors stimulated these osteoclasts with tumour necrosis factor α (TNFα) and detected the phosphorylation of kinases by western blot. Gene expression of osteoclasts was detected by real-time PCR. Histomorphometrie showed increased trabecular volume and trabecular number and decreased trabecular separation in MK2 deficient mice compared to wildtype. The μCT analysis confirmed these results and showed an increased bone density in MK2 deficient mice. Thus the four point bending experiment demonstrated a higher mechanical stability of bone of these mice. The number of osteoclasts was reduced while the number of osteoblasts was not altered in MK2 deficient mice. Serum Osteocalcin and RatLaps levels were decreased while OPG was increased and RANKL was not altered. Ex vivo osteoclastogenesis was clearly reduced in MK2 deficient mice compared to wildtype mice while the number of CD11b precursors in the bone marrow was equal. The phosphorylation of p38, serine/threonine protein kinase (AKT) and extracellular signal regulated kinase (ERK) was increased in TNFα stimulated MK2 deficient osteoclasts. Gene expression of TRAP, osteoclast associated receptor (OSCAR), matrix metalloproteinase 9 and receptor activator of nuclear factor κB (RANK) was decreased in MK2 deficient osteoclasts. MK2 deficient mice have an increased bone density and a reduced number of osteoclasts. This is due to impaired osteoclastogenesis in consequence of reduced expression of osteoclast specific genes. Thus MK2 plays an important role in physiological bone turnover by regulating osteoclastogenesis.</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkDtPwzAUhS0EEqXwB5giMTC5-BXbGauqBdryGKADi-U4TkmbJsVOKvrvcVQEEhPT1dH97tG5B4BLjAYYU36jXTYgqFNMJjweEHwEephxCQni6Bj0EEIUsoSLU3Dm_SpIJLHsgfHD8HkGtWmKnW5sFm1d3diiitZFpb2FJHJ22ZZh5aPt-94XdVkvC6PLKK0rGzWtq-qddefgJNeltxffsw9eJ-OX0R2cP93ej4ZzmBJCMZSUC5rGNrYyM5TzxCY0z1iqU2k4SQixklKe81gYbGTKDM5NTHKhs1RokRPaB9cH3xDzo7W-UZvCG1uWurJ161WCGOOcURzIqz_kqg5hQziFhRCSJywWgSIHyrjae2dztXXFRru9wkh1xapQrOqKVYdiFems4eGo8I39_LnQbq3CeyJWj4uRmi7e6HQymyv2y6eb1X_8vwBTQ4hj</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Braun, Tobias</creator><creator>Lepper, Johannes</creator><creator>Lezuo, Patrick</creator><creator>Schett, Georg</creator><creator>Zwerina, Jochen</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope></search><sort><creationdate>20110301</creationdate><title>MAPK-activated protein kinase-2 regulates physiological bone turnover</title><author>Braun, Tobias ; Lepper, Johannes ; Lezuo, Patrick ; Schett, Georg ; Zwerina, Jochen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2231-83673b5e5e8dc3669e93fd4bab8c62922e8336f657c1c8b4c1fc52f7adb7a7f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Braun, Tobias</creatorcontrib><creatorcontrib>Lepper, Johannes</creatorcontrib><creatorcontrib>Lezuo, Patrick</creatorcontrib><creatorcontrib>Schett, Georg</creatorcontrib><creatorcontrib>Zwerina, Jochen</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Braun, Tobias</au><au>Lepper, Johannes</au><au>Lezuo, Patrick</au><au>Schett, Georg</au><au>Zwerina, Jochen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAPK-activated protein kinase-2 regulates physiological bone turnover</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>70</volume><issue>Suppl 2</issue><spage>A21</spage><epage>A22</epage><pages>A21-A22</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is a main target of MAPK p38, a key intracellular signal transduction molecule mediating osteoclastogenesis and inflammation. MK2 deficient mice are healthy and fertile in contrast to p38 deficient mice. Aim of this study is to determine whether MK2 contributes to the regulation of physiological bone turnover and to identify a potential mechanism. To determine the bone phenotype the authors analysed a Tartrate resistant acid phosphatase (TRAP)-staining and a goldner staining of the tibia by histomorphometrie and did a μCT scan of the tibia. The mechanical stability of the bone was detected using the four point bending experiment. Serum bone turnover markers (Osteocalcin and RatLaps) and serum level of Receptor activator of nuclear factor κB ligand (RANKL) and Osteoprotegrin (OPG) were detected by ELISA. To analyse osteoclastogenesis the authors determined the number of osteoclast precursor cells in the bone marrow by Fluoreszenz activated cell sorter (FACS) and generated osteoclasts from bone marrow cells ex vivo. To analyse intracellular signalling pathways, the authors stimulated these osteoclasts with tumour necrosis factor α (TNFα) and detected the phosphorylation of kinases by western blot. Gene expression of osteoclasts was detected by real-time PCR. Histomorphometrie showed increased trabecular volume and trabecular number and decreased trabecular separation in MK2 deficient mice compared to wildtype. The μCT analysis confirmed these results and showed an increased bone density in MK2 deficient mice. Thus the four point bending experiment demonstrated a higher mechanical stability of bone of these mice. The number of osteoclasts was reduced while the number of osteoblasts was not altered in MK2 deficient mice. Serum Osteocalcin and RatLaps levels were decreased while OPG was increased and RANKL was not altered. Ex vivo osteoclastogenesis was clearly reduced in MK2 deficient mice compared to wildtype mice while the number of CD11b precursors in the bone marrow was equal. The phosphorylation of p38, serine/threonine protein kinase (AKT) and extracellular signal regulated kinase (ERK) was increased in TNFα stimulated MK2 deficient osteoclasts. Gene expression of TRAP, osteoclast associated receptor (OSCAR), matrix metalloproteinase 9 and receptor activator of nuclear factor κB (RANK) was decreased in MK2 deficient osteoclasts. MK2 deficient mice have an increased bone density and a reduced number of osteoclasts. This is due to impaired osteoclastogenesis in consequence of reduced expression of osteoclast specific genes. Thus MK2 plays an important role in physiological bone turnover by regulating osteoclastogenesis.</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/ard.2010.148965.21</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2011-03, Vol.70 (Suppl 2), p.A21-A22 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_miscellaneous_904466431 |
source | BMJ Journals - NESLi2 |
title | MAPK-activated protein kinase-2 regulates physiological bone turnover |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A36%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAPK-activated%20protein%20kinase-2%20regulates%20physiological%20bone%20turnover&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Braun,%20Tobias&rft.date=2011-03-01&rft.volume=70&rft.issue=Suppl%202&rft.spage=A21&rft.epage=A22&rft.pages=A21-A22&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2010.148965.21&rft_dat=%3Cproquest_cross%3E904466431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777869457&rft_id=info:pmid/&rfr_iscdi=true |